(Circulation. 2001;104:376.)
© 2001 American Heart Association, Inc.
Brief Rapid Communications |
Cerivastatin, a Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor, Improves Endothelial Function in Elderly Diabetic Patients Within 3 Days
From the Department of Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, and the Department of Cardiovascular Medicine (K.E.), Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Correspondence to Toshio Hayashi, Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550 Japan. E-mail hayashi{at}med.nagoya-u.ac.jp
Background— The short-term effects of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) on endothelial function at doses that do not affect plasma lipid levels are not known.
Methods and Results— We investigated the short-term effects of cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, on endothelial function and endothelium-related products in elderly diabetic patients. Twenty-seven elderly diabetic patients (aged 69.3±3.4 years), with or without mild hypercholesterolemia, were enrolled in this study, which tested cerivastatin treatment (0.15 mg/d) for 3 days. Endothelium-dependent flow-mediated dilatation, endothelium-independent dilatation by nitroglycerin in the brachial artery, nitric oxide-related products (nitrite/nitrate and cGMP), endothelium-related products (von Willebrand Factor, soluble vascular cell adhesion molecule-1, and soluble intercellular adhesion molecule-1), and a marker of oxidant stress (8-isoprostane) were assessed. Levels of plasma lipids were not changed before and after treatment with cerivastatin. Flow-mediated dilatation was significantly increased by cerivastatin treatment, as were plasma nitrite/nitrate levels (from 16.9±3.4 to 22.0±3.7 µmol/L, P<0.05) and cGMP values. The percent of nitroglycerin-induced dilatation was not changed. Plasma concentrations of 8-isoprostane decreased, and levels of soluble vascular cell adhesion molecule also tended to decrease with cerivastatin.
Conclusions— Improvement of endothelial function was in line with antiatherosclerotic effects. Cerivastatin improved impaired endothelial function in the short-term without affecting lipid profiles in elderly diabetic patients. This effect may be partly due to upregulation of endothelial nitric oxide synthase.
Key Words: diabetes mellitus • aging • endothelium • nitric oxide • hyperlipidemia
This article has been cited by other articles:
 |
|
 |
|
  P. Strazzullo, S. M. Kerry, A. Barbato, M. Versiero, L. D'Elia, and F. P. Cappuccio Do Statins Reduce Blood Pressure?: A Meta-Analysis of Randomized, Controlled Trials Hypertension, April 1, 2007; 49(4): 792 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Douglas, P. G. O'Malley, and J. L. Jackson Meta-Analysis: The Effect of Statins on Albuminuria Ann Intern Med, July 18, 2006; 145(2): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Suzuki, M. Saito, T. Nagai, H. Saeki, and Y. Kazatani Prevention of Positive Coronary Artery Remodeling with Statin Therapy in Patients with Coronary Artery Diseases Angiology, May 1, 2006; 57(3): 259 - 265. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Nagaoka, A. Takahashi, E. Sato, N. Izumi, T. W. Hein, L. Kuo, and A. Yoshida Effect of systemic administration of simvastatin on retinal circulation. Arch Ophthalmol, May 1, 2006; 124(5): 665 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Danford Outcome After Surgical Repair of Single Ventricle AAP Grand Rounds, July 1, 2005; 14(1): 2 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Beishuizen, J. T. Tamsma, J. W. Jukema, M. A. van de Ree, J. C. M. van der Vijver, A. E. Meinders, and M. V. Huisman The Effect of Statin Therapy on Endothelial Function in Type 2 Diabetes Without Manifest Cardiovascular Disease Diabetes Care, July 1, 2005; 28(7): 1668 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ceriello, R. Assaloni, R. Da Ros, A. Maier, L. Piconi, L. Quagliaro, K. Esposito, and D. Giugliano Effect of Atorvastatin and Irbesartan, Alone and in Combination, on Postprandial Endothelial Dysfunction, Oxidative Stress, and Inflammation in Type 2 Diabetic Patients Circulation, May 17, 2005; 111(19): 2518 - 2524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, S. Schulz, C. Manes, D. Fischer, K. de Groot, D. Fliser, et al. Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans Circulation, May 10, 2005; 111(18): 2356 - 2363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E C Jury and M R Ehrenstein Statins: immunomodulators for autoimmune rheumatic disease? Lupus, March 1, 2005; 14(3): 192 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 M. L. Bots, J. Westerink, T. J. Rabelink, and E. J.P. de Koning Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response Eur. Heart J., February 2, 2005; 26(4): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saliashvili, W. W. Davis, M. T. Harris, N.-A. Le, and W. V. Brown Simvastatin Improved Arterial Compliance in High-Risk Patients Vascular and Endovascular Surgery, November 1, 2004; 38(6): 519 - 523. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Li, S.-P. Zhao, D.-q. Peng, Z.-m. Xu, and H.-n. Zhou Early Effect of Pravastatin on Serum Soluble CD40L, Matrix Metalloproteinase-9, and C-Reactive Protein in Patients with Acute Myocardial Infarction Clin. Chem., September 1, 2004; 50(9): 1696 - 1699. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kitamoto, K. Nakano, Y. Hirouchi, Y. Kohjimoto, S. Kitajima, M. Usui, S. Inoue, and K. Egashira Cholesterol-Lowering Independent Regression and Stabilization of Atherosclerotic Lesions by Pravastatin and by Antimonocyte Chemoattractant Protein-1 Therapy in Nonhuman Primates Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1522 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.J. Halcox and J. E. Deanfield Beyond the Laboratory: Clinical Implications for Statin Pleiotropy Circulation, June 1, 2004; 109(21_suppl_1): II-42 - II-48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Wolfram Kuhlmann, C. Gast, F. Li, M. Schafer, H. Tillmanns, B. Waldecker, and J. Wiecha Cerivastatin Activates Endothelial Calcium-Activated Potassium Channels and Thereby Modulates Endothelial Nitric Oxide Production and Cell Proliferation J. Am. Soc. Nephrol., April 1, 2004; 15(4): 868 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Economides, A. Caselli, E. Tiani, L. Khaodhiar, E. S. Horton, and A. Veves The Effects of Atorvastatin on Endothelial Function in Diabetic Patients and Subjects at Risk for Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 740 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Sommeijer, M. R. MacGillavry, J. C.M. Meijers, A. P. Van Zanten, P. H. Reitsma, and H. T. Cate Anti-Inflammatory and Anticoagulant Effects of Pravastatin in Patients With Type 2 Diabetes Diabetes Care, February 1, 2004; 27(2): 468 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wassmann, A. Faul, B. Hennen, B. Scheller, M. Bohm, and G. Nickenig Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function Circ. Res., October 31, 2003; 93 (9): e98 - e103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.P. Brandes, S. Beer, T. Ha, and R. Busse Withdrawal of Cerivastatin Induces Monocyte Chemoattractant Protein 1 and Tissue Factor Expression in Cultured Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1794 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mochizuki, H. Vink, O. Hiramatsu, T. Kajita, F. Shigeto, J. A. E. Spaan, and F. Kajiya Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H722 - H726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ceriello New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy Diabetes Care, May 1, 2003; 26(5): 1589 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.O Bonetti, L.O Lerman, C Napoli, and A Lerman Statin effects beyond lipid lowering--are they clinically relevant? Eur. Heart J., February 1, 2003; 24(3): 225 - 248. [Full Text] [PDF]
|
|
|
|
|
|
T. Tsunekawa, T. Hayashi, Y. Suzuki, H. Matsui-Hirai, H. Kano, A. Fukatsu, N. Nomura, A. Miyazaki, and A. Iguchi Plasma Adiponectin Plays an Important Role in Improving Insulin Resistance With Glimepiride in Elderly Type 2 Diabetic Subjects Diabetes Care, February 1, 2003; 26(2): 285 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kawashima, T. Yamashita, Y. Miwa, M. Ozaki, M. Namiki, T. Hirase, N. Inoue, K.-i. Hirata, and M. Yokoyama HMG-CoA Reductase Inhibitor Has Protective Effects Against Stroke Events in Stroke-Prone Spontaneously Hypertensive Rats Stroke, January 1, 2003; 34(1): 157 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ceriello, C. Taboga, L. Tonutti, L. Quagliaro, L. Piconi, B. Bais, R. Da Ros, and E. Motz Evidence for an Independent and Cumulative Effect of Postprandial Hypertriglyceridemia and Hyperglycemia on Endothelial Dysfunction and Oxidative Stress Generation: Effects of Short- and Long-Term Simvastatin Treatment Circulation, September 3, 2002; 106(10): 1211 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.E. Deanfield The management of special patient populations Eur. Heart J. Suppl., September 1, 2002; 4(suppl_F): F19 - F23. [Abstract] [PDF]
|
|
|
|
|
|
S. Delbosc, J.-P. Cristol, B. Descomps, A. Mimran, and B. Jover Simvastatin Prevents Angiotensin II-Induced Cardiac Alteration and Oxidative Stress Hypertension, August 1, 2002; 40(2): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vecchione and R. P. Brandes Withdrawal of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Elicits Oxidative Stress and Induces Endothelial Dysfunction in Mice Circ. Res., July 26, 2002; 91(2): 173 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kluft Is C-reactive protein an additional, surrogate end-point for statin treatment? Eur. Heart J., May 2, 2002; 23(10): 761 - 764. [Full Text] [PDF]
|
|
|
|
|
|
W.F. Riesen, H. Engler, M. Risch, W. Korte, and G. Noseda Short-term effects of atorvastatin on C-reactive protein Eur. Heart J., May 2, 2002; 23(10): 794 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. van Etten, E. J.P. de Koning, M. L. Honing, E. S. Stroes, C. A. Gaillard, and T. J. Rabelink Intensive Lipid Lowering by Statin Therapy Does Not Improve Vasoreactivity in Patients With Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 799 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dechend, D. Muller, J. K. Park, A. Fiebeler, H. Haller, and F. C. Luft Statins and angiotensin II-induced vascular injury Nephrol. Dial. Transplant., March 1, 2002; 17(3): 349 - 353. [Full Text] [PDF]
|
|
|
|
|
|
S. Wassmann, U. Laufs, K. Muller, C. Konkol, K. Ahlbory, A. T. Baumer, W. Linz, M. Bohm, and G. Nickenig Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 300 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hashimoto, H. Akita, T. Hayashi, T. Tsunekawa, H. Kano, D. Sumi, H. Matsui-Hirai, N. K. Thakur, A. Iguchi, and K. Egashira Cerivastatin, a Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor, Improves Endothelial Function in Elderly Diabetic Patients Within 3 Days Response Circulation, January 29, 2002; 105 (4): e30 - e31. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Stein, C. M. Carlsson, T. Hayashi, T. Tsunekawa, H. Kano, D. Sumi, H. Matsui-Hirai, N. K. Thakur, A. Iguchi, and K. Egashira Cerivastatin and Endothelial Function in Elderly Patients With Diabetes Mellitus Response Circulation, January 29, 2002; 105 (4): e32 - e33. [Full Text] [PDF]
|
|